Abstract
Parkinson’s disease (PD) is a degenerative movement disorder that affects 7 to 10 million people worldwide. The cardinal clinical features of PD are resting tremor, muscle rigidity, bradykinesia, and postural instability. These movement abnormalities are principally caused by death of dopamine-producing neurons in the substantia nigra. Most patients in early-stage PD respond well to medical therapy, usually levodopa, which alleviates these cardinal symptoms by replacing dopamine. After years of levodopa therapy, however, many patients develop motor fluctuations and experience an increase in “off” time (periods of time where the benefits of medications are limited). Deep brain stimulation (DBS) therapy is a surgical treatment that dramatically improves motor fluctuations as well as the principal features of bradykinesia, tremor, and rigidity. Additionally, DBS can be used to treat medication-induced dyskinesias. Although DBS therapy does not slow the progression of PD, it has been proven to improve motor fluctuations and quality of life beyond what can be achieved with best medical therapy. Patient selection is critically important in order to obtain these significant benefits, and dopamine responsiveness is a key diagnostic test. Due to the heterogeneity of PD symptoms and the complexity of accurate diagnosis, a team process for patient selection should be used. In this chapter, we will review the indications and patient selection criteria for DBS therapy for Parkinson’s disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525–35.
Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003;348(14):1356–64.
Dorsey ER, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–6.
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52.
Gasser T. Usefulness of genetic testing in PD and PD trials: a balanced review. J Parkinsons Dis. 2015;5:209–15.
Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol. 2003;53(Suppl 3):S16–23. discussion S23–25
Selikhova M, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain. 2009;132(Pt 11):2947–57.
Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499–504.
Movement Disorder Society Task Force on Rating Scales for Parkinson's, Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738–50.
Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–76.
Hauser RA, Auinger P, Parkinson Study G. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord. 2011;26(5):813–8.
Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615–22.
Galvan A, Wichmann T. Pathophysiology of parkinsonism. Clin Neurophysiol. 2008;119(7):1459–74.
Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord. 2015;30(1):19–36.
Olanow CW, Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord. 2013;28(1):31–40.
Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211.
Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci. 2010;1184:188–95.
Cedarbaum JM, et al. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol. 1986;9(2):153–9.
Nelson MV, et al. Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin Neuropharmacol. 1989;12(2):91–7.
Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969;280(7):337–45.
Olanow CW. Levodopa: effect on cell death and the natural history of Parkinson's disease. Mov Disord. 2015;30(1):37–44.
Fahn S, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498–508.
Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665–77.
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.
Cilia R, et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731–42.
Parkinson Study G. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287(13):1653–61.
Whone AL, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93–101.
American Academy of Neurology. Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia. 2006; Available from: aan.com/guidelines.
Olanow CW, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.
Guridi J, Lozano AM. A brief history of pallidotomy. Neurosurgery. 1997;41(5):1169–80. discussion 1180-3
Speelman JD, Bosch DA. Resurgence of functional neurosurgery for Parkinson's disease: a historical perspective. Mov Disord. 1998;13(3):582–8.
DeLong MR, et al. The contribution of basal ganglia to limb control. Prog Brain Res. 1986;64:161–74.
Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249(4975):1436–8.
Pollak P, et al. Effects of the stimulation of the subthalamic nucleus in Parkinson disease. Rev Neurol (Paris). 1993;149(3):175–6.
McCairn KW, Turner RS. Deep brain stimulation of the globus pallidus internus in the parkinsonian primate: local entrainment and suppression of low-frequency oscillations. J Neurophysiol. 2009;101(4):1941–60.
Brown P. Bad oscillations in Parkinson's disease. J Neural Transm Suppl. 2006;70:27–30.
Wingeier B, et al. Intra-operative STN DBS attenuates the prominent beta rhythm in the STN in Parkinson's disease. Exp Neurol. 2006;197(1):244–51.
Shimamoto SA, et al. Subthalamic nucleus neurons are synchronized to primary motor cortex local field potentials in Parkinson's disease. J Neurosci. 2013;33(17):7220–33.
Chiken S, Nambu A. Disrupting neuronal transmission: mechanism of DBS? Front Syst Neurosci. 2014;8:33.
Deuschl G, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896–908.
Weaver FM, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79(1):55–65.
Odekerken VJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12(1):37–44.
Krack P, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003;349(20):1925–34.
Hamani C, et al. Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature. Neurosurgery. 2005;56(6):1313–21. discussion 1321-4
Kleiner-Fisman G, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290–304.
Okun MS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol. 2009;65(5):586–95.
Limousin P, et al. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry. 1999;66(3):289–96.
Aviles-Olmos I, et al. Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry. 2014;85(12):1419–25.
Funkiewiez A, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834–9.
Weintraub D, et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2013;84(10):1113–8.
Weintraub D, et al. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015;30(2):121–7.
Tarsy D, et al. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor. Stereotact Funct Neurosurg. 2005;83(5–6):222–7.
Bang Henriksen, M., et al., Surviving 10 years with deep brain stimulation for Parkinson's disease - a follow-up of 79 patients. Eur J Neurol, 2014. (in press).
Okun MS, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol. 2005;62(8):1250–5.
Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31(3):140–9.
Hughes AJ, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.
Schuepbach WM, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610–22.
Mestre TA, et al. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. Mov Disord. 2014;29(14):1751–6.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42.
Bronstein JM, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68(2):165.
Castrioto A, et al. Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. Lancet Neurol. 2014;13(3):287–305.
Massano J, Garrett C. Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review. Front Neurol. 2012;3:66.
Lang AE, et al. Deep brain stimulation: preoperative issues. Mov Disord. 2006;21(Suppl 14):S171–96.
Llebaria G, et al. Cut-off score of the Mattis dementia rating scale for screening dementia in Parkinson's disease. Mov Disord. 2008;23(11):1546–50.
Witt K, et al. Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease. J Neurol Sci. 2011;310(1–2):261–6.
Daniele A, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74(2):175–82.
Rughani AI, Hodaie M, Lozano AM. Acute complications of movement disorders surgery: effects of age and comorbidities. Mov Disord. 2013;28(12):1661–7.
Welter ML, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain. 2002;125(Pt 3):575–83.
Derost PP, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology. 2007;68(17):1345–55.
Follett KA, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010;362(22):2077–91.
Anderson VC, et al. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol. 2005;62(4):554–60.
Hartinger M, et al. Effects of medication and subthalamic nucleus deep brain stimulation on tongue movements in speakers with Parkinson's disease using electropalatography: a pilot study. Clin Linguist Phon. 2011;25(3):210–30.
Putzer M, Barry WJ, Moringlane JR. Effect of bilateral stimulation of the subthalamic nucleus on different speech subsystems in patients with Parkinson's disease. Clin Linguist Phon. 2008;22(12):957–73.
Krack P, Hariz MI. Deep brain stimulation in Parkinson's disease: reconciliation of evidence-based medicine with clinical practice. Lancet Neurol. 2013;12(1):25–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Brock, A., Hardy, M., House, P. (2019). Indications for Deep Brain Stimulation Therapy in Parkinson’s Disease. In: Goodman, R. (eds) Surgery for Parkinson's Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-23693-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-23693-3_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-23692-6
Online ISBN: 978-3-319-23693-3
eBook Packages: MedicineMedicine (R0)